Apparatus

Carvykti gains new ground and competes with its "predecessor"!

Recently, Nassim Annabi, an assistant professor of Northeastern University in the United States, and other researchers from the University of Sydney in Australia jointly developed an advanced surgical glue MeTro. When using, the glue directly enters the wound and is solidified and sealed within 60 seconds. Naxim said, "The advantage of MeTro formula is that once it touches the organ, it will appear as gel instantly and will not slip."

New therapy for lung cancer!

Misconceptions about how to treat a sore throat are fuelling the overuse of antibiotics, according to STAR research.

According to data from an ongoing Phase I/Ib clinical trial (NCT04374877), an innovative IL-27 inhibitor called SRF388 has shown promising results in the treatment of locally advanced or advanced non-small cell lung cancer (NSCLC), which undoubtedly brings new hope for the treatment of lung cancer patients in general!

Nectin-4 is an important target that has been shown to be available as a treatment for locally advanced and advanced bladder cancer. Based on this, Padcev (enfortumab-vedotin-ejfv), the first ADC drug (antibody-coupled drug) for uroepithelial carcinoma, has also received accelerated FDA approval for the treatment of locally advanced or advanced bladder cancer in patients who have previously received immune checkpoint inhibitors (PD-L1, PD-1) and platinum-containing chemotherapy before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy). Adult patients with advanced or late-stage uroepithelial carcinoma (a common type of bladder cancer).

In a rural area of Britain, a team of 100 scientists and engineers first used low-cost technologies to develop mobile phones and the aviation industry. Later, these technologies were used to research robot arms, which can be specially used for minimally invasive surgery.

The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.

A new approach to cancer treatment!

Data from a study of a cancer vaccine combined with a PD-1 immune checkpoint inhibitor has recently been released, and the treatment has increased the survival of patients with advanced colorectal cancer by more than three times, with some patients surviving for more than 22 months so far.